To print: Select File and then Print from your browser's menu

Title: European Union Approves Brinzolamide/Timolol Suspension for the Treatment of Glaucoma, Ocular Hypertension

"European Union Approves Brinzolamide/Timolol Suspension for the Treatment of Glaucoma, Ocular Hypertension"

NEW YORK -- December 3, 2008 -- The European Medicines Agency has approved the fixed combination brinzolamide 10 mg/mL plus timolol 5 mg/mL (Azarga) ophthalmic suspension for the treatment of elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension in adult patients for whom monotherapy provides insufficient IOP reduction. The approval is based on 2 studies that showed brinzolamide/timolol to be more comfortable and better tolerated by patients than dorzolamide plus timolol (Cosopt). In a patient preference study comparing the 2 solutions, 79% of patients with glaucoma expressed a preference to brinzolamide/timolol. The studies also showed that the active ingredients in the brinzolamide/timolol suspension were more effective when delivered in combination than either of them individually. Brinzolamide/timolol demonstrated superior IOP-lowering efficacy at every time point measured in the study versus the individual components alone, while demonstrating a similar safety profile. In addition, a head-to-head study showed that brinzolamide/timolol provides IOP lowering efficacy that is similar to dorzolamide/timolol. SOURCE: Alcon, Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.